Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, July 21, 2017
[ Fri, Jul 21st 2017
] - WOPRAI
[ Fri, Jul 21st 2017
] - WOPRAI
[ Fri, Jul 21st 2017
] - WOPRAI
[ Fri, Jul 21st 2017
] - WOPRAI
[ Fri, Jul 21st 2017
] - WOPRAI
[ Fri, Jul 21st 2017
] - WOPRAI
[ Fri, Jul 21st 2017
] - WOPRAI
[ Fri, Jul 21st 2017
] - WOPRAI
[ Fri, Jul 21st 2017
] - WOPRAI
[ Fri, Jul 21st 2017
] - WOPRAI
[ Fri, Jul 21st 2017
] - WOPRAI
Thu, July 20, 2017
[ Thu, Jul 20th 2017
] - WOPRAI
[ Thu, Jul 20th 2017
] - WOPRAI
[ Thu, Jul 20th 2017
] - WOPRAI
[ Thu, Jul 20th 2017
] - WOPRAI
[ Thu, Jul 20th 2017
] - WOPRAI
[ Thu, Jul 20th 2017
] - WOPRAI
[ Thu, Jul 20th 2017
] - WOPRAI
[ Thu, Jul 20th 2017
] - WOPRAI
[ Thu, Jul 20th 2017
] - WOPRAI
[ Thu, Jul 20th 2017
] - WOPRAI
[ Thu, Jul 20th 2017
] - WOPRAI
[ Thu, Jul 20th 2017
] - WOPRAI
Matthew Harrison Maintained (SRPT) at Hold with Increased Target to $33 on, Jul 20th, 2017
Matthew Harrison of Morgan Stanley, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Hold with Increased Target from $31 to $33 on, Jul 20th, 2017.
Matthew has made no other calls on SRPT in the last 4 months.
There is 1 other peer that has a rating on SRPT. Out of the 1 peers that are also analyzing SRPT, 0 agree with Matthew's Rating of Hold.
This is the rating of the analyst that currently disagrees with Matthew
- Mike Guo of "SunTrust Robinson Humphrey" Upgraded from Hold to Strong Buy on, Wednesday, April 5th, 2017
